Antonelli Incalzi, Raffaele
Consoli, Agostino
Lopalco, Pierluigi
Maggi, Stefania
Sesti, Giorgio http://orcid.org/0000-0002-1618-7688
Veronese, Nicola
Volpe, Massimo
Funding for this research was provided by:
Università degli Studi di Roma La Sapienza
Article History
Received: 7 June 2023
Accepted: 8 October 2023
First Online: 27 October 2023
Declarations
:
: RAI and GS declare that they have no conflicts of interest. AC declares the following COI: Bristol Myer Squibb, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dhome, Novartis, Novo-Nordisk, Sanofi-Aventis, Sigma-Tau, Takeda (speaker), Astra Zeneca, Bristol Myer Squibb, Boehringer Ingelheim, Eli Lilly, GSK, Merck Sharp & Dhome, Novo-Nordisk.(Advisory Board) Astra Zeneca, Novo-Nordisk (consultant) Astra Zeneca, Eli Lilly, Novo-Nordisk (research grant). PL received research grants and personal fees as advisory board member and/or speaker from GSK, Moderna, MSD, Novavax, Pfizer and Sanofi. SM received research grants and personal fees as advisory board member and/or speaker from GSK, Pfizer, Merck, Sanofi, Takeda, Novavax, Viatris and Janssen. NV received personal fees from IBSA, Mylan, Viatris, Fidia, MSD, Bayer and Sanofi-Aventis. MV served as a consultant in advisory boards of Sanofi Pasteur and GSK.